Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode.
Copyright: epstock / 123RF Stock Photo
On December 18, 2025, Werewolf Therapeutics, Inc. shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and next-generation INDUCER T cell engager platform. Management said they observed strong monotherapy and combination activity with WTX-124 in heavily pretreated melanoma, cutaneous squamous cell carcinoma, and gastroesophageal junction cancer, with objective response rates of 21-30% in select populations. Tumor regression in roughly 33% of lesions was reported, alongside a favorable tolerability profile, including no vascular leak syndrome and manageable grade 3-4 adverse events (27/106 and 2/106). Moreover, the FDA accepted 18mg as the recommended dose, providing guidance for a monotherapy registration path in relapsed/refractory melanoma.
At the same time, WTX-330 continues to demonstrate strong momentum, showing promising antitumor activity in difficult-to-treat cancers, along with an optimized manufacturing process that enhances safety, pharmacokinetics, and therapeutic index. A 45% reduction in tumor lesions was confirmed in one partial response in metastatic gall bladder cancer. Werewolf Therapeutics, Inc. aims to mark the completion of Phase 1/1b WTX-124 and early Phase 1b/2 WTX-330 studies in the first half of 2026, while finalizing strategic partners to advance its INDUKINE programs.
Werewolf Therapeutics, Inc. focuses on developing tumor-activated immunotherapies for cancer using its Predator and INDUCER platforms.
READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.
